Maxlinear Asia Singapore PTE LTD

Maxlinear Asia Singapore PTE LTD has been granted 53 US utility patents between 2016 and 2020, placing Maxlinear Asia Singapore PTE LTD at rank #6,361 across all assignees tracked by PlainPatent. This portfolio spans 14 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.3 claims per patent with primary concentration in H04B (TRANSMISSION). As a Foreign Corporation, Maxlinear Asia Singapore PTE LTD is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 38.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 2 grants, compared with 51 in the 2015–2019 window — a -96% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Maxlinear Asia Singapore PTE LTD's 19.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 14 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Maxlinear Asia Singapore PTE LTD against peers pursuing similar technology classes.